|Description||(Z)-JIB-04 is a Z-isomer of JIB-04, which is a small-molecule histone demethylase inhibitor with antitumor activity. JIB-04 selectively inhibits tumor growth via targeting various tumorigenic signaling pathways.|
|B0084-284797||50 mg||$298||In stock|
|Related CAS||199596-05-9 (JIB-04)|
|Synonyms||5-Chloro-2-(2-(phenyl(pyridin-2-yl)methylene)hydrazinyl)pyridine; JIB-04 Z-isomer|
(Z)-JIB-04 is a Z-isomer of JIB-04, which is a small-molecule histone demethylase inhibitor with antitumor activity. JIB-04 selectively inhibits tumor growth vi...
ML 324 dihydrochloride is an inhibitor of Jumonji domain-containing protein 2 (JMJD2) histone demethylase. It potently suppresses herpes simplex virus (HSV) IE ...
GSK2879552 has been found to be a LSD1 inhibitor that could have antineoplastic effect through restraining the growth of overexpressed tumor cells. It was just ...
GSK-J2, a benzazepin derivative, has been found to have poor activity as a JMJD3 inhibitor so that could be used in the biological study of GSK-J1 as a negative...
KDM5-inhibitor is an analog of CPI-455, a selective KDM5 inhibitor. CPI-455 increases levels of H3K4 trimethylation (H3K4me3) and decreases the number of DTPs i...
TC-E 5002 is a selective histone demethylase KDM2/7 subfamily inhibitor (IC50 = 0.2, 1.2, 6.8, 55, 83, >100 and >120 μM for KDM7A, KDM7B, KDM2A, KDM5A, KDM4C, K...
CBB1007, an amidino-guanidinium derivative, has been found to have biological activity in anticancer-study by acting as a LSD1 inhibitor. IC50: 5.27 uM.
GSK J4 HCl
GSK J4 HCl is a cell permeable prodrug of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM and i...